17 research outputs found
ASSESSMENT OF REFRACTORY GOLD-BEARING ORES BASED OF INTERPRETATION OF THERMAL ANALYSIS DATA
The article presents the results of a study on the possibility to assess refractory gold-bearing ores using thermal analysis data. It studies the flotation concentrates obtained during the enrichment of double refractory sulfide gold-bearing ores. This type of ore is complicated by the fine impregnation of gold in sulphide minerals and the presence of sorption-active scattered carbonaceous matter, which is in close association with sulphides. The results of thermogravimetric and mass spectrometric studies of refractory gold-bearing ores are presented.
The obtained fragments for kerogen CHΒ (m/zΒ =Β 15), C2HΒ (m/zΒ =Β 29) and C3HΒ (m/zΒ =Β 43) indicate the presence of various types of carbonaceous matter in the studied samples. It is justified that the degree of sorption activity of carbonaceous matter depends on the presence of kerogen and bitumen in the ore. High sorption activity of scattered carbonaceous material significantly affects the processing technology of ores and concentrates, both flotation and pyro- and hydrometallurgical methods.
Thermogravimetric and mass spectroscopic analyzes can be used to determine the degree of preg-robbing of refractory gold-bearing ores. The obtained results predetermine the direction of creating new methods and technologies in the field of decarburization of refractory gold-bearing ores in the integrated development of solid minerals in the mining regions of Russia
Π¦Π²Π΅ΡΠΎΠ²Π°Ρ Π΄Π΅ΡΠΈΡΡΠΎΠ²ΠΊΠ° ΡΠ΅ΡΠ½ΠΎ-Π±Π΅Π»ΡΡ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΠΌΠΌ ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΎΡΡΠΈ Π² Π½ΠΎΡΠΌΠ΅
Colour identification of normal black-and-white chest radiograms using the UAR-2 imaging device has provided additional abilities to study all the parts of pleura, lung tissue, stroma and lung vessels as well as to get the information on density, width and area of different mediastinal parts. A correlation between coloured imaging data and constitution, gender and age has been established.ΠΡΠΈ ΡΠ²Π΅ΡΠΎΠ²ΠΎΠΉ Π΄Π΅ΡΠΈΡΡΠΎΠ²ΠΊΠ΅ ΡΠ΅ΡΠ½ΠΎ-Π±Π΅Π»ΡΡ
ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΠΌΠΌ ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΎΡΡΠΈ Π² Π½ΠΎΡΠΌΠ΅ Π½Π° ΡΠ΅Π»Π΅Π²ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ ΡΡΡΠ°Π½ΠΎΠ²ΠΊΠ΅ Π£ΠΠ -2 ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π΄Π»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π²ΡΠ΅Ρ
ΠΎΡΠ΄Π΅Π»ΠΎΠ² ΠΏΠ»Π΅Π²ΡΡ, Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, ΡΡΡΠΎΠΌΡ ΠΈ ΡΠΎΡΡΠ΄ΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄Π»Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΎ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ, ΡΠΈΡΠΈΠ½Π΅ ΠΈ ΠΏΠ»ΠΎΡΠ°Π΄ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ°ΡΡΠ΅ΠΉ ΡΡΠ΅Π΄ΠΎΡΡΠ΅Π½ΠΈΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ Π΄Π°Π½Π½ΡΡ
ΡΠ²Π΅ΡΠΎΠ²ΠΎΠ³ΠΎ ΠΈΠ·ΠΎΠ±ΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΎΡ ΠΊΠΎΠ½ΡΡΠΈΡΡΡΠΈΠΈ, ΠΏΠΎΠ»Π° ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΠ°
ΠΠ΅Π³ΠΎΡΠ½Π°Ρ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡ, ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π±Π»Π΅ΠΎΠΌΠΈΡΠΈΠ½ΠΎΠΌ, Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π»ΠΈΠΌΡΠΎΠΌΠΎΠΉ Π₯ΠΎΠ΄ΠΆΠΊΠΈΠ½Π°
Bleomycin used as part of many chemo-therapeutic programs for treating Hodgkin lymphoma is associated with pulmonary toxicity. Development of complications after mediastinal radiotherapy is also well-known. However, the synergistic effect of the combination of radiotherapy and bleomycin is considered in the literature much less frequently and mainly when using the total focal doses (SOD) of 36 β 40 Gy. Since 1998 the chemo-radiotherapeutic regimens applied to the treatment of Hodgkin lymphoma in the MRRC (Obninsk) has involved subradical TTD of 20 β 30 Gy. The goal of the study is to evaluate pulmonary toxicity in Hodgkin lymphoma patients treated with chemo-radiotherapy involving ABVD and mediastinal treatment with TTD of 20 β 30 Gy.Methods. A series of 142 Hodgkin lymphoma patients received ABVD and mediastinal radiotherapy at the TTD 20 β 30 Gy. Conventional film and digital chest X-rays, linear and digital tomograms taken at different stages of treatment and follow up were analysed.Results. Changes in lungs in the form of a pathologic pulmonary pattern (interstitial pneumonitis) were seen in 39 (27.5%) of 142 patients. In 10 (25.6%) of 39 patients focal or confluent pneumonitis infiltration were found, that was 7% of the whole study group. Clinical evidence of bleomycin-induced pneumonitis was found in 6 (15.4%) of 39 patients. With follow-up terms up to 60 months fibrotic changes in lungs were absent. The occurrence of radiation pneumonitis was 17.6%, radiation fibrosis β 35.9%. Fibrotic changes were mainly grade 1 (94.1%). In HL patients with bleomycin-induced pneumonitis the occurrence of radiation pneumonitis was 43.6% (17 of 39 patients), radiation fibrosis β 58.9% (23 of 39 patients) while the corresponding figures for patients who did not have bleomycin-induced pneumonitis were 8.7% (9 of 103 patients) and 27.2% (28 of 103 patients), respectively (p < 0.001).Conclusion. A statistically significant increase in occurrence of radiation pneumonitis and radiation fibrosis was defined in HL patients who suffered bleomycin-induced pneumonitis.ΠΠ»Π΅ΠΎΠΌΠΈΡΠΈΠ½, Π²Ρ
ΠΎΠ΄ΡΡΠΈΠΉ Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ ΡΡ
Π΅ΠΌ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ (Π₯Π’) Π±ΠΎΠ»ΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΠΌΠΎΠΉ Π₯ΠΎΠ΄ΠΆΠΊΠΈΠ½Π° (ΠΠ₯), ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ. Π’Π°ΠΊΠΆΠ΅ ΠΈΠ·Π²Π΅ΡΡΠ½Ρ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ ΠΎΠ±Π»Π°ΡΡΠΈ ΡΡΠ΅Π΄ΠΎΡΡΠ΅Π½ΠΈΡ. Π‘ΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ Π»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ Π±Π»Π΅ΠΎΠΌΠΈΡΠΈΠ½Π° ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ Π² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ΅ΠΆΠ΅ ΠΈ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠΌΠΌΠ°ΡΠ½ΡΡ
ΠΎΡΠ°Π³ΠΎΠ²ΡΡ
Π΄ΠΎΠ· (Π‘ΠΠ) ΠΎΠ± Π»ΡΡΠ΅Π½ΠΈΡ 36β 40 ΠΡ. Π‘ 1998 Π³. ΠΏΡΠΈ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (Π₯ΠΠ’) Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ₯ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΡΡΠ±ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΡΠ΅ Π‘ΠΠ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ 20β30 ΠΡ.Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ₯ ΠΏΡΠΈ Π₯ΠΠ’ β ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Π₯Π’ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ABVD ΠΈ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ ΡΡΠ΅Π΄ΠΎΡΡΠ΅Π½ΠΈΡ Π² Π‘ΠΠ 20β30 ΠΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΠ₯ (n = 142), ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΠ΅ Π₯Π’ ABVD ΠΈ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ΅Π΄ΠΎΡΡΠ΅Π½ΠΈΡ Π² Π‘ΠΠ 20β30 ΠΡ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΠΈΡΡΠΎΠ²ΡΠ΅ ΠΎΠ±Π·ΠΎΡΠ½ΡΠ΅ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΠΌΠΌΡ, Π»ΠΈΠ½Π΅ΠΉΠ½ΡΠ΅ ΠΈ ΡΠΈΡΡΠΎΠ²ΡΠ΅ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΡΠ΅ ΡΠΎΠΌΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ, Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π½ΡΠ΅ Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ°ΠΏΠ°Ρ
Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π»Π΅Π³ΠΊΠΈΡ
ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Ρ 39 (27,5 %) ΠΈΠ· 142 Π±ΠΎΠ»ΡΠ½ΡΡ
Π² Π²ΠΈΠ΄Π΅ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅Π³ΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΡΡΠ½ΠΊΠ° (ΠΈΠ½ΡΠ΅ΡΡΡΠΈΡΠΈΠ°Π»ΡΠ½ΡΠΉ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΈΡ). Π 10 (25,6 %) ΡΠ»ΡΡΠ°ΡΡ
ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»Π°ΡΡ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ ΠΎΡΠ°Π³ΠΎΠ²ΠΎΠ³ΠΎ ΠΈΠ»ΠΈ ΡΠ»ΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠΎΠ² (ΠΎΡΠ°Π³ΠΎΠ²ΡΠΉ, ΡΠ»ΠΈΠ²Π½ΠΎΠΉ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΈΡ), (7 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΡΠ΅ΠΉ Π³ΡΡΠΏΠΏΡ). ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π±Π»Π΅ΠΎΠΌΠΈΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΈΡΠ° (ΠΠ) ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Ρ 6 (15,4 %) Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΡΠΈ ΡΡΠΎΠΊΠ°Ρ
Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π΄ΠΎ 60 ΠΌΠ΅Ρ. ΡΠΈΠ±ΡΠΎΠ·Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π»Π΅Π³ΠΊΠΈΡ
Π²Π½Π΅ ΠΏΠΎΠ»Π΅ΠΉ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ. Π§Π°ΡΡΠΎΡΠ° Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΈΡΠ° (ΠΠ) ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 17,6 %, Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΎΠ·Π° β 35,9 %. ΠΡΠΌΠ΅ΡΠ΅Π½Ρ ΡΠ°ΠΊΠΆΠ΅ ΡΠΈΠ±ΡΠΎΠ·Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ I ΡΡΠ΅ΠΏΠ΅Π½ΠΈ (94,1 %). Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ₯, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΠ, ΡΠ°ΡΡΠΎΡΠ° ΠΠ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 17 (43,6 %) ΠΈΠ· 39 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΎΠ·Π° β 23 (58,9 %), Ρ Π»ΠΈΡ, Π½Π΅ ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΠ, β 9 (8,7 %) ΠΈ 28 (27,2 %) ΠΈΠ· 103 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ) (p < 0,001).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΠΠ ΠΈ Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΎΠ·Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ₯, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΠ
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ICG-ΠΊΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°ΠΊΠΎΠΌ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ I ΡΡΠ°Π΄ΠΈΠΈ
Background. Lymphatic spread is the main route of metastasis in early stage endometrial cancer. Considering its significance, three risk factors of lymph node metastasis were identified. At a high risk of lymph node metastasis in patients with stage I endometrial cancer, pelvic and lumbar lymph node dissection is recommended. In low-risk patients, lymph node dissection is not performed. Lymph node dissection in medium-risk patients is considered as a staging procedure. However, in patients with aggravating factors that prevent extended hysterectomy, lymph node biopsy with ICG mapping and subsequent microstaging may be an alternative to lymph node dissection. Purpose of the study: to analyze the effectiveness of surgical approaches for staging endometrial cancer at different risk factors for lymphatic metastasis.Material and Methods. The treatment outcomes were retrospectively analyzed in 565 patients with stage I endometrial cancer treated at the gynecological oncology department of Botkin City Clinical Hospital and at the gynecological oncology department of Kaluga Regional Clinical Oncology Center from 2021 to 2023. All women were divided into three groups according to the risk factors of lymph node metastasis. Patients underwent hysterectomy, hysterectomy combined with pelvic or pelvic and lumbar lymphadenectomy, as well as hysterectomy with ICG mapping and sentinel lymph node biopsy.Results. A total of 334 endometrial cancer patients underwent surgery at Botkin City Clinical Hospital. In the medium-risk group patients (n=94), who underwent hysterectomy with pelvic (n=36) and pelvic + lumbar lymphadenectomy (n=31), lymph node metastases were detected in 4 (11.1 %) and 6 (19.4 %) patients, respectively. In the high-risk group (n=50) with similar surgeries, metastatic lymph nodes were identified in 2 (10.5 %, n=19) and 6 (26.1 %, n=23) patients, respectively. At Kaluga Regional Oncology Center, 231 patients underwent hysterectomy with sentinel lymph node biopsy. The low-risk group, the medium-risk group, and the high-risk group showed lymph node metastases in 7 (5.47 %), 6 (10.2 %), and 6 (13.6 %) patients, respectively.Conclusion. In stage I endometrial cancer patients with a low risk of lymph node metastasis, hysterectomy with sentinel lymph node biopsy is recommended. For medium-and high-risk groups, hysterectomy with systemic lymphadenectomy is recommended. If it is not possible to remove the pelvic and lumbar lymph nodes, their biopsy with ICG mapping and microstaging can be recommended. A combination of systemic lymphadenectomy with sentinel lymph node biopsy is a promising technique that could hypothetically demonstrate better results in terms of disease staging.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΈΠΌΡΠΎΠ³Π΅Π½Π½ΡΠΉ ΠΏΡΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΏΡΠΈ Π½Π°ΡΠ°Π»ΡΠ½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΡΠ°ΠΊΠ° ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ. Π£ΡΠΈΡΡΠ²Π°Ρ Π΅Π³ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ, Π²ΡΠ΄Π΅Π»Π΅Π½Ρ ΡΡΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° Π»ΠΈΠΌΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠΈ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠ°ΠΌ Ρ I ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ΅ΡΡΡ Π»ΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΡ ΡΠ°Π·ΠΎΠ²ΡΡ
ΠΈ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ², ΠΏΡΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ β ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² Π½Π΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡ. ΠΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΡ Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ² ΠΏΡΠΈ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½ΠΈΡΡΡΡ ΠΊΠ°ΠΊ ΡΡΠ°Π΄ΠΈΡΡΡΡΡΡ ΠΏΡΠΎΡΠ΅Π΄ΡΡΡ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ ΠΎΡΡΠ³ΠΎΡΠ°ΡΡΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΏΡΠ΅ΠΏΡΡΡΡΠ²ΡΡΡΠΈΡ
ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ°ΡΡΠΈΡΠ΅Π½Π½ΠΎΠΉ Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΠΈ, Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π±ΠΈΠΎΠΏΡΠΈΡ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ² Ρ ICG-ΠΊΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ ΠΌΠΈΠΊΡΠΎΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² Π΄Π»Ρ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ΅ΠΏΠ΅Π½ΡΡ
ΡΠΈΡΠΊΠ° Π»ΠΈΠΌΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ 565 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ I ΡΡΠ°Π΄ΠΈΠΈ Π² ΠΎΠ½ΠΊΠΎΠ³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ ΠΠΎΡΠΎΠ΄ΡΠΊΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»ΡΠ½ΠΈΡΡ ΠΈΠΌ. Π‘.Π. ΠΠΎΡΠΊΠΈΠ½Π° ΠΈ ΠΎΠ½ΠΊΠΎΠ³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ ΠΠ°Π»ΡΠΆΡΠΊΠΎΠ³ΠΎ ΠΎΠ±Π»Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΠ° Ρ 2021 ΠΏΠΎ 2023 Π³. ΠΡΠ΅ ΠΆΠ΅Π½ΡΠΈΠ½Ρ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° ΡΡΠΈ Π³ΡΡΠΏΠΏΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° Π»ΠΈΠΌΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ. ΠΠ°ΡΠΈΠ΅Π½ΡΠΊΠ°ΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Ρ Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΡ, Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΡ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ ΠΈΠ»ΠΈ Ρ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ ΠΈ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΠ΅ΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΡ Ρ ICG-ΠΊΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈ Π±ΠΈΠΎΠΏΡΠΈΠ΅ΠΉ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΎΠ½ΠΊΠΎΠ³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ ΠΠΎΡΠΎΠ΄ΡΠΊΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»ΡΠ½ΠΈΡΡ ΠΈΠΌ. Π‘.Π. ΠΠΎΡΠΊΠΈΠ½Π° Π±ΡΠ»ΠΎ ΠΏΡΠΎΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½ΠΎ 334 ΠΆΠ΅Π½ΡΠΈΠ½Ρ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΠΈΡΠΊΠ° (n=94) ΠΏΠΎΡΠ»Π΅ Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΠΈ Ρ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ ΠΈ Ρ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ (n=36) ΠΈ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΠ΅ΠΉ (n=31) Π²ΡΡΠ²Π»Π΅Π½ΠΎ 4 (11,1 %) ΠΈ 6 (19,4 %) ΡΠ»ΡΡΠ°Π΅Π² ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. Π Π³ΡΡΠΏΠΏΠ΅ Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° (n=50) ΠΏΠΎΡΠ»Π΅ Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΡ
ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π»ΠΈΠΌΡΠΎΡΠ·Π»Ρ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Ρ 2 (10,5 %, n=19) ΠΈ 6 (26,1 %, n=23) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ. Π ΠΠ°Π»ΡΠΆΡΠΊΠΎΠΌ ΠΎΠ±Π»Π°ΡΡΠ½ΠΎΠΌ Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΠ΅ ΠΏΡΠΎΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π° 231 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠ°; Π²ΡΠ΅ΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΡ Ρ Π±ΠΈΠΎΠΏΡΠΈΠ΅ΠΉ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ². ΠΡΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° Π²ΡΡΠ²Π»Π΅Π½ΠΎ 7 (5,47 %) ΡΠ»ΡΡΠ°Π΅Π² ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΠ·Π»ΠΎΠ², ΠΏΡΠΈ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎΠΉ β 6 (10,2 %), ΠΏΡΠΈ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ β 6 (13,6 %) ΡΠ»ΡΡΠ°Π΅Π² Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π² Π»ΠΈΠΌΡΠΎΡΠ·Π»Π°Ρ
.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ I ΡΡΠ°Π΄ΠΈΠΈ Ρ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΠΈΡΠΊΠ° Π»ΠΈΠΌΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ Π²ΡΠΏΠΎΠ»Π½ΡΡΡ Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΡ Ρ Π±ΠΈΠΎΠΏΡΠΈΠ΅ΠΉ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ². ΠΡΠΈ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎΠΉ ΠΈ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΊΠ° ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ΅ΡΡΡ Π³ΠΈΡΡΠ΅ΡΡΠΊΡΠΎΠΌΠΈΡ Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΠ΅ΠΉ. ΠΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΡΠ°Π·ΠΎΠ²ΡΡ
ΠΈ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΌΠΎΠΆΠ½ΠΎ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°ΡΡ ΠΈΡ
Π±ΠΈΠΎΠΏΡΠΈΡ Ρ ICG-ΠΊΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈ ΠΌΠΈΠΊΡΠΎΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ. ΠΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΡΡΡΡ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠ°Π΄Π΅Π½ΡΠΊΡΠΎΠΌΠΈΠΈ Ρ Π±ΠΈΠΎΠΏΡΠΈΠ΅ΠΉ ΡΡΠΎΡΠΎΠΆΠ΅Π²ΡΡ
Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ Π³ΠΈΠΏΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΌΠΎΠ³ΡΡ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°ΡΡ Π»ΡΡΡΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Ρ ΠΏΠΎΠ·ΠΈΡΠΈΠΈ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ